Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Le Kremlin-Bicetre – page 20

297 clinical trials in Le Kremlin-Bicetre, France across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Le Kremlin-Bicetre at a glance
297
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

297 trials in Le Kremlin-Bicetre

Open in trial search

Bladder cancer

Not recruiting

Study of Atezolizumab with BCG Treatment for Patients with High-Risk Non-Muscle Invasive Bladder Cancer Who Have Not Previously Received BCG

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Atezolizumab
  • Sponsor:Unicancer

Pituitary-dependent Cushing's syndrome

Not recruiting

Study of Osilodrostat for Children and Adolescents with Cushing's Disease

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Osilodrostat
  • Sponsor:Recordati AG

Sepsis

Not recruiting

Study of hydrocortisone and fludrocortisone combination versus placebo in adults with sepsis in intensive care unit to determine corticosteroid response

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Betamethasone
  • Sponsor:Assistance Publique Hopitaux De Paris

Pulmonary hypertension

Not recruiting

Study on the Effects of Riociguat and Macitentan in Patients with Inoperable Chronic Thromboembolic Pulmonary Hypertension

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Macitentan
  • Sponsor:Assistance Publique Hopitaux De Paris

Colorectal cancer+1

Not recruiting

Study on Oxaliplatin and Irinotecan for Patients with Metastatic Colorectal Cancer in the Liver

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Oxaliplatin
  • Sponsor:Fondation Franc.Cancerologie Digestive

Immune thrombocytopenia

Not recruiting

Study comparing dexamethasone versus immunoglobulin plus prednisone for adults with immune thrombocytopenia (ITP) who have moderate to severe bleeding

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Assistance Publique Hopitaux De Paris

Giant cell arteritis

Not recruiting

Study on Tocilizumab and Steroids for Patients with Giant Cell Arteritis and Cerebrovascular Involvement

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Tocilizumab
  • Sponsor:Assistance Publique Hopitaux De Paris

Haemophilia B with anti factor IX+1

Not recruiting

Study on How Concizumab Works for Patients with Hemophilia A or B with Inhibitors

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Concizumab
  • Sponsor:Novo Nordisk A/S

Autoimmune demyelinating disease

Not recruiting

Study on the Effects of Satralizumab for Patients with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)

Registered drug
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Relapsing-remitting multiple sclerosis

Not recruiting

Study on the Safety and Effectiveness of Ocrelizumab vs. Fingolimod for Children and Adolescents with Relapsing-Remitting Multiple Sclerosis

Registered drug
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:DIMENHYDRINATE
  • Sponsor:F. Hoffmann-La Roche AG

Pulmonary arterial hypertension

Not recruiting

Study on the Safety and Effectiveness of Cibotercept (KER-012) with Other Drugs for Adults with Pulmonary Arterial Hypertension

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cibotercept
  • Sponsor:Keros Therapeutics Inc.

Still's disease

Not recruiting

Study on the Safety and Effectiveness of Baricitinib and Tocilizumab for Children with Systemic Juvenile Idiopathic Arthritis

Registered drug
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Baricitinib
  • Sponsor:Eli Lilly & Co.

Other cities in France

The busiest research cities in the country

All 380 cities in France

Clinical research in Le Kremlin-Bicetre

What the registry says about research in the country

01 Gastroenterology Research

Innovative studies exploring treatments for inflammatory bowel diseases, with multiple trials investigating fecal microbiota transplantation as a therapeutic approach for Crohn's disease and ulcerative colitis. Research focuses on maintaining remission and improving patient outcomes.

  • Crohn's Disease Management
  • Ulcerative Colitis Treatment
  • Microbiota-Based Therapies
02 Neurology Studies

Clinical research targeting neurological conditions, including trials for Myasthenia Gravis and innovative treatments for aneurysmal subarachnoid hemorrhage. Studies aim to improve daily living activities and patient outcomes.

  • Myasthenia Gravis Treatment
  • Subarachnoid Hemorrhage Management
  • Neurological Disorders
03 Immunology & Rheumatology

Comprehensive research into autoimmune conditions, including studies on rheumatoid arthritis and Sjögren's syndrome. Trials evaluate novel therapeutic approaches and maintenance treatments for improved disease management.

  • Rheumatoid Arthritis Therapies
  • Sjögren's Syndrome Research
  • Immune System Disorders
04 Pulmonary Medicine

Advanced research in respiratory conditions, including studies on pulmonary hypertension, severe asthma, and interstitial lung disease. Trials focus on evaluating new treatments and improving patient care strategies.

  • Pulmonary Hypertension
  • Severe Asthma Management
  • Lung Fibrosis Treatment
Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.